Share on StockTwits

Isis Pharmaceuticals (NASDAQ:ISIS) CEO Stanley Crooke unloaded 12,500 shares of Isis Pharmaceuticals stock on the open market in a transaction that occurred on Wednesday, January 8th. The stock was sold at an average price of $40.05, for a total transaction of $500,625.00. Following the completion of the transaction, the chief executive officer now directly owns 1,661 shares in the company, valued at approximately $66,523. The transaction was disclosed in a document filed with the SEC, which is available at this link.

A number of analysts have recently weighed in on ISIS shares. Analysts at Piper Jaffray upgraded shares of Isis Pharmaceuticals from an “underweight” rating to a “neutral” rating in a research note to investors on Tuesday, November 26th. They now have a $38.00 price target on the stock, up previously from $25.00. Analysts at Zacks reiterated a “neutral” rating on shares of Isis Pharmaceuticals in a research note to investors on Thursday, November 7th. They now have a $33.00 price target on the stock. One research analyst has rated the stock with a sell rating, six have given a hold rating and four have issued a buy rating to the company. The stock currently has an average rating of “Hold” and an average price target of $36.18.

Shares of Isis Pharmaceuticals (NASDAQ:ISIS) traded up 3.14% during mid-day trading on Friday, hitting $47.60. The stock had a trading volume of 2,118,521 shares. Isis Pharmaceuticals has a 52-week low of $12.78 and a 52-week high of $46.51. The stock’s 50-day moving average is $39.00 and its 200-day moving average is $32.90. The company’s market cap is $5.525 billion.

Isis Pharmaceuticals (NASDAQ:ISIS) last issued its quarterly earnings data on Tuesday, November 5th. The company reported ($0.21) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.27) by $0.06. The company had revenue of $23.60 million for the quarter, compared to the consensus estimate of $19.82 million. During the same quarter last year, the company posted ($0.37) earnings per share. Isis Pharmaceuticals’s revenue was up 103.4% compared to the same quarter last year. On average, analysts predict that Isis Pharmaceuticals will post $-0.52 earnings per share for the current fiscal year.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.